| Previous Close | 0.17 |
| Open | 0.18 |
| Bid | 0.17 x 0 |
| Ask | 0.18 x 0 |
| Day's Range | 0.17 - 0.18 |
| 52 Week Range | 0.17 - 1.09 |
| Volume | 224,530 |
| Avg. Volume | 135,077 |
| Market Cap | 13.953M |
| Beta | -2.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.16 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
VANCOUVER, British Columbia, Aug. 15, 2018-- Veritas Pharma Inc. is pleased to announce that it has signed a Memorandum of Understanding with IsCann Group Limited located in Be'er Tuvya, Israel with the ...
VANCOUVER, British Columbia, Aug. 13, 2018-- Veritas Pharma Inc. is pleased to announce that it has entered into a Memorandum of Understanding with the Chamber of Commerce, Industry, Services and Tourism ...
VANCOUVER, British Columbia, Aug. 08, 2018-- Veritas Pharma Inc. is pleased to announce that Clearstream Banking, a major central securities depository based in Frankfurt, Germany, which announced on June ...
VANCOUVER, British Columbia, July 27, 2018-- Veritas Pharma Inc. is pleased to announce that effective June 25, 2018, it cancelled a total of 3,272,000 incentive stock options granted under the Company’ ...
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce that it has signed an Intellectual Property Sharing Agreement (“Joint IP”) with Sativa Investments PLC (“Sativa”) (NEX:SATI), UK’s first medicinal cannabis investment fund. Veritas through its subsidiary company, Cannevert Therapeutics Ltd., will apply its pharmacological methods on cannabis strain lead selection to assist Sativa’s application to the UK Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing license.
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F) (“Veritas” or the “Company”) is pleased to announce that Mr. Filios Theodorou has been appointed as its business development agent in Cyprus. Currently, medical cannabis is legal in Cyprus, nonetheless doctors may only prescribe it to patients suffering from specific ailments, typically as a last resort and strictly for palliative care.
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) with Colombian medical cannabis company Foliumed S.A.S. (“Foliumed”). Under the terms of the MOU, Veritas and Foliumed will jointly conduct scientific research, undertake product development activities, and commercialize select medical cannabis products with the help of Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”).
Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to provide a corporate update on its achievements, related scientific activities and growth strategies for the second quarter of fiscal 2018. Earlier this year, Veritas Pharma’s subsidiary Cannevert Therapeutics (“CTL”) signed an agreement with Puerto Rico’s Fundación de Investigación (“FDI”) Clinical Research to perform trials of its lead cannabis strain, CTL-X, to target pain.